Background A newer generation bioresorbable scaffold Firesorb(MicroP ort,Shanghai,China),with thinner-strut(100~125μm),is constructed from a PLLA backbone abluminally coated with a PDLLA layer eluting sirolimus.FUTUR...Background A newer generation bioresorbable scaffold Firesorb(MicroP ort,Shanghai,China),with thinner-strut(100~125μm),is constructed from a PLLA backbone abluminally coated with a PDLLA layer eluting sirolimus.FUTURE-I study intended to assess the feasibility,preliminary safety and effectiveness of the Firesorb BRS in patients with single de novo coronary artery lesions.We evaluated the long-term performance of the new generation BRS with thinner struts serially(post-procedure,at 6 months,1,2 year)after implantation.展开更多
Background Current studies,including randomized trials and meta-analyses evaluating clinical Results of bioresorbable scaffold(BRS),have raised concerns about the first-generation device with thicker struts and limite...Background Current studies,including randomized trials and meta-analyses evaluating clinical Results of bioresorbable scaffold(BRS),have raised concerns about the first-generation device with thicker struts and limited expansion capability.Newer BRS with thinner struts and improved deliverability are expected to enhance safety and efficacy profile.Bioheart(Bio-Heart,Shanghai,China)BRS is constructed from a PLLA backbone coated with a PDLLA layer eluting sirolimus.Sixmonth Results have proved preliminary safety and effectiveness of the Bioheart BRS in patients with single de novo coronary artery lesions.We sought to report serial intracoronary imaging findings at 1 year.展开更多
Background and Objective Previous reports from PANDA III trial had proven that BuMA biodegradable polymer(BP)sirolimus-elutingstents(SES),with faster drug eluting rate and polymer absorption kinetics,was non-inferior ...Background and Objective Previous reports from PANDA III trial had proven that BuMA biodegradable polymer(BP)sirolimus-elutingstents(SES),with faster drug eluting rate and polymer absorption kinetics,was non-inferior to the Excel SES in an all-comers population for 1-year target lesion failure(TLF),with a lower incidence of stent thrombosis(ST).The aim of the present study was to perform a safety evaluation of BuMA SES in the complex patient and lesion subgroup.展开更多
文摘Background A newer generation bioresorbable scaffold Firesorb(MicroP ort,Shanghai,China),with thinner-strut(100~125μm),is constructed from a PLLA backbone abluminally coated with a PDLLA layer eluting sirolimus.FUTURE-I study intended to assess the feasibility,preliminary safety and effectiveness of the Firesorb BRS in patients with single de novo coronary artery lesions.We evaluated the long-term performance of the new generation BRS with thinner struts serially(post-procedure,at 6 months,1,2 year)after implantation.
文摘Background Current studies,including randomized trials and meta-analyses evaluating clinical Results of bioresorbable scaffold(BRS),have raised concerns about the first-generation device with thicker struts and limited expansion capability.Newer BRS with thinner struts and improved deliverability are expected to enhance safety and efficacy profile.Bioheart(Bio-Heart,Shanghai,China)BRS is constructed from a PLLA backbone coated with a PDLLA layer eluting sirolimus.Sixmonth Results have proved preliminary safety and effectiveness of the Bioheart BRS in patients with single de novo coronary artery lesions.We sought to report serial intracoronary imaging findings at 1 year.
文摘Background and Objective Previous reports from PANDA III trial had proven that BuMA biodegradable polymer(BP)sirolimus-elutingstents(SES),with faster drug eluting rate and polymer absorption kinetics,was non-inferior to the Excel SES in an all-comers population for 1-year target lesion failure(TLF),with a lower incidence of stent thrombosis(ST).The aim of the present study was to perform a safety evaluation of BuMA SES in the complex patient and lesion subgroup.
